Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Muscular Dystrophies
Lancet 394:2025-2038, Mercuri, E.,et al, 2019
Factor Xa Inhibitors Versus Vitamin K Antagonists for Prevention of Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 49:e235-e236, Bruins Slot, K.M.H. & Berge, E., 2018
Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018
Ischemic Optic Neuropathies
NEJM 372:2428-2436, Biousse, V. & Newman, N.J., 2015
Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
JAMA 311:682-691, Porsteinsson, A.P.,et al, 2014
Using Dabigatran in Patients with Stroke A Practical Guide for Clinicians
Stroke 43:271-279, Alberts, M.J.,et al, 2012
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Infectious and Non-Infectious Neurologic Complications in Heart Transplant Recipients
Medicine 89:166-175, Mu�oz,P., et al, 2010
Evidence Report: The Efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:1463-1470, Marriott,J.J., et al, 2010
Cardiotoxicity and Other Adverse Events Associated With Mitoxantrone Treatment for MS
Neurol 74:1822-1826, Kingwell,E., et al, 2010
Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
NEJM 360:2066-2078,2127, The ACTIVE Investigators, 2009
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? No
Stroke 40:1944-1945,1946, Fisher,M., 2009
Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009
Managing the Anticoagulated Patient with Atrial Fibrillation at High Risk of Stroke Who Needs Coronary Intervention
BMJ 337:1110-1111, Lip,G.Y.H., 2008
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007
Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials
Stroke 38:874-880, Akins,P.T.,et al, 2007
ADHD Drugs and Cardiovascular Risk
NEJM 354:1445-1448, Nissen,S.E., 2006
Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005
Ximelagatran--Promises and Concerns
JAMA 293:736-739, Gurewich,V., 2005
Treatment of Parkinson's Disease with Pergolide and Relation to Restrictive Valvular Heart Disease
Lancet 363:1179-1183, Van Camp,G.,et al, 2004
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Heart Valvular Disease in Patients with Parkinson's Disease Treated with High-Dose Pergolide
Neurol 61:859-861, VanCamp,G.,et al, 2003
The Safety of Triptans in the Treatment of Patients with Migraine
Am J Med 112:135-140, Jamieson,D.G., 2002
Cardiac Adverse Effects Associated with Mitoxantrone (Novantrone) Therapy in Patients with MS
Neurol 59:909-913, Ghalie,R.G.,et al, 2002
Optimal Intensity of Warfarin Therapy for Secondary Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation
Stroke 31:817-821, Yamaguchi,T., 2000
Near-Fatal Heat Stroke During the 1995 Heat Wave in Chicago
Ann Int Med 129:173-181, Damatte,J.E.,et al, 1998
Medical Causes of Seizures
Lancet 352:383-390, Delanty,N.,et al, 1998
Dystonia and Chorea in Acquired Systemic Disorders
JNNP 65:436-445, Janavs,J.L.&Aminoff,M.J., 1998
Cost Effectiveness of Oral Compared with IV Antibiotic Therapy for Pts with Early Lyme Dis or Lyme Arthritis
NEJM 337:357-363, Eckman,M.H.,et al, 1997
Seizures in Medically Complex Patients
Epilepsia 38:S55-S59, Boggs,J.G., 1997
Complications of Intravenous Immune Globulin Treatment in Neurologic Disease
Neurol 47:674-677, Brannagan III,T.H.,et al, 1996
Intravenous IgG in Guillain-Barre Syndrome
BMJ 313:376-377, Hughes,R.A.C., 1996
Linomide Reduces the Rate of Active Lesions in Relapsing-Remitting Multiple Sclerosis
Neurol 47:895-900, Anderson,O.,et al, 1996
Neurotoxicity in Liver Transplant Recipients with Cyclosporine Immunosuppression
Neurol 45:1962-1964, Wijdicks,E.F.M.,et al, 1995
Intracerebral Hemorrhage Complicating Urokinase Infusion Into an Occluded Aortocoronary Bypass Graft
Cathet Cardiovasc Diagn 31:206-210, Taylor,M.A.,et al, 1994
Cabergoline in Parkinson's Disease:Long-Term Follow-up
Neurol 43:2587-2590, Lera,G.,et al, 1993
Neurological Complications Following Liver Transplantation
Ann Neurol 31:644-649, Stein,D.P.,et al, 1992
Coronary Vasospasm Induced by Subcutaneous Sumatriptan
BMJ 304:1415, Willett,F.,et al, 1992
Evaluation and Management of the Patient with Syncope
JAMA 268:2553-2560, Kapoor,W.N., 1992
Irregular Breathing
In Internal Medicine, Little, Brown & Co, Boston, 3rd Ed, p. 573-574, Cherniack,N.S., 1990
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Phase 2 Trial of Difelikefalin in Notalgia Paresthetica
NEJM 388:511-517, Kin,B.S.,et al, 2023
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023